Your browser doesn't support javascript.
loading
Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma
Guinot, J. L; Tortajada, M. I; Carrascosa, M; Crispín, V; Otero, A; Ríos, B; Rivin, E; Santos, M; Soler, P; Arribas, L.
Affiliation
  • Guinot, J. L; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Tortajada, M. I; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Carrascosa, M; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Crispín, V; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Otero, A; Hospital Reina Sofía. Córdoba. Spain
  • Ríos, B; Hospital Virgen de las Nieves. Granada. Spain
  • Rivin, E; Hospital Reina Sofía. Córdoba. Spain
  • Santos, M; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Soler, P; Fundación Instituto Valenciano de Oncología. Valencia. Spain
  • Arribas, L; Fundación Instituto Valenciano de Oncología. Valencia. Spain
Clin. transl. oncol. (Print) ; 14(2): 109-115, feb. 2012. ilus, tab
Article in English | IBECS | ID: ibc-126109
Responsible library: ES1.1
Localization: BNCS
ABSTRACT

PURPOSE:

We present the results of a prospective ten-year follow-up study to prove the effectiveness of a single fraction of 192-Ir high-dose-rate (HDR) brachytherapy (BT) as a boost. PATIENTS AND

METHODS:

Between 1999 and 2000, 84 consecutive patients with invasive breast carcinoma, with over 4 mm free margins after conservative surgery, were treated. All cases were stages T1-2, except for one case, a stage T3, 81% pN0, 19% pN1-2. Chemotherapy was used in 47% and hormonal therapy in 87%. Whole breast external beam radiotherapy (46 Gy) was followed 1-2 weeks later by an implant with metallic needles. A 7 Gy single dose of HDR BT to the 90% isodose line was delivered on an outpatient basis. Dosimetry was performed theoretically. This technique is called FAST-boost because the whole treatment is delivered in about two hours.

RESULTS:

With a median follow-up of 120 months, three patients relapsed in the margin of the implant and two in a different quadrant (5/84, 6%). Actuarial local control at five and ten years was 98.5% and 95.6%. Overall survival was 92.7% and 90.2%, and disease-free survival 90.2% and 79.9%. Cosmetic results were good or excellent in 92.5%.

CONCLUSIONS:

A single-fraction HDR boost with rigid needles (FAST-boost) is a good, quick, simple technique when surgical margins are free (AU)
Subject(s)
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Breast Cancer Database: IBECS Main subject: Brachytherapy / Breast Neoplasms / Carcinoma, Papillary / Clinical Trials as Topic / Carcinoma, Lobular / Carcinoma, Ductal, Breast Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2012 Document type: Article Institution/Affiliation country: Fundación Instituto Valenciano de Oncología/Spain / Hospital Reina Sofía/Spain / Hospital Virgen de las Nieves/Spain
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Breast Cancer Database: IBECS Main subject: Brachytherapy / Breast Neoplasms / Carcinoma, Papillary / Clinical Trials as Topic / Carcinoma, Lobular / Carcinoma, Ductal, Breast Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2012 Document type: Article Institution/Affiliation country: Fundación Instituto Valenciano de Oncología/Spain / Hospital Reina Sofía/Spain / Hospital Virgen de las Nieves/Spain
...